Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SWM-XXX
- Development stage
- Unknown
- Lead developer
- Swarm Oncology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SWM-XXX is an autologous T cell therapy developed by Swarm Oncology using its proprietary Swarm-T platform. The therapy is engineered to recognize patient-specific tumor neoantigens, which are unique mutations found only in the patient's tumor cells. By isolating and expanding T cells that target these neoantigens, the treatment aims to provide a highly personalized and precise immune response against solid tumors. SWM-XXX is currently being evaluated for the treatment of various malignancies, including head and neck cancer, breast cancer, and colorectal cancer, with the goal of minimizing off-target effects and enhancing anti-tumor efficacy.
- Other names
- Swarm-T platform therapyautologous neoantigen-specific T cell therapy
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on SWM-XXX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SWM-XXX.